Connect with others who understand.

Sign up Log in
Resources
About MyMyelomaTeam
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Has Anyone Successfully Used Dara And Dex As First Line Treatment? Does Blood Type Play Into Any Treatment Decsions?

A MyMyelomaTeam Member asked a question 💭
California, CA

Diagnosed as IgA, kappa 20% BMB & High Risk - deletion 17p

October 3
View reactions
A MyMyelomaTeam Member

I highly recommend Dr Brandy’s book “Beat Back Cancer Naturally “. Dr Brandy has MM and is doing very well by changing his diet and taking supplements.
Paula🌹

October 3
A MyMyelomaTeam Member

Hi Katherine,
Have you been diagnosed as Smoldering or MM? I am IgA Kappa with 20% bad plasma and t(14;16). 16q deletion, Monosomy 13 and +5. Since I am only 20% I am Smoldering. I have never heard that blood type matters. It might, but I haven’t come across any research on it.
Paula🌹

October 3
A MyMyelomaTeam Member

Has anyone successfully used Dara and Dex as first-line treatment?

- Daratumumab (Dara) and dexamethasone (Dex) are commonly used in treating multiple myeloma. Daratumumab is a monoclonal antibody that targets the CD38 protein on myeloma cells, helping the immune system fight the cancer. It has been a breakthrough in Show Full Answer

Has anyone successfully used Dara and Dex as first-line treatment?

- Daratumumab (Dara) and dexamethasone (Dex) are commonly used in treating multiple myeloma. Daratumumab is a monoclonal antibody that targets the CD38 protein on myeloma cells, helping the immune system fight the cancer. It has been a breakthrough in myeloma treatment and is often used in combination with other drugs.

Does blood type play into any treatment decisions?

- Blood type does not typically influence treatment decisions for multiple myeloma. Treatment choices are more often based on factors like genetic markers (e.g., deletion 17p), the type of myeloma (e.g., IgA, kappa), and the patient's overall health and response to previous treatments.

Diagnosed as IgA, kappa 20% BMB & high risk - deletion 17p

- Being diagnosed with IgA, kappa myeloma and having high-risk features like deletion 17p can influence treatment decisions. High-risk genetic markers may lead doctors to choose more aggressive or combination therapies to manage the disease effectively.

October 3

Related content

View All

Darzalex Approved For Newly Diagnosed Multiple Myeloma Patients

A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA

Looking For N-of-1 Stories (We’re All A Unique “Case Of One”)

A MyMyelomaTeam Member asked a question 💭

Dara Faspro, Pomalyst, Dexamethasone

A MyMyelomaTeam Member asked a question 💭
Lincoln, NE
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data Policy and Privacy policies.Your privacy is our priority Lock Icon
Already a Member? Log in